ClinicalTrials.gg
CompletedNCT02953314Updated Mar 4, 2020Results posted

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)

A Phase 3 interventional study of TEZ and TEZ/IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 33 sites in 2 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2020-03-04.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
83
Allocation
Non-randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.

Enrollment
25th of 43
83 · median 100
Started
2016
with 5 others
Phase 3
25 of 43
none open now
Registered
11th of 43
by date
Lead sponsor
39 of 43
Vertex Pharmaceuticals Incorporated

Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 25th largest by enrollment, is one of 6 that started in 2016, is one of 25 in phase 3, and was the 11th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tezacaftor

tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tezacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This is a Phase 3, 2-part (Part A and Part B), open label, multicenter study evaluating the pharmacokinetic (PK), safety, and tolerability of multiple doses of tezacaftor (TEZ) in combination with ivacaftor (IVA) in subjects 6 through 11 years of age with CF who are homozygous or heterozygous for the F508del- CF transmembrane conductance regulator protein (CFTR) mutation.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who weigh ≥15 kg without shoes at the Screening Visit.
  • All genotypes as specified by the study protocol are eligible in Part A.
  • The following genotypes are eligible in Part B:

    • homozygous for the F508del CFTR mutation
    • heterozygous for the F508del CFTR mutation and with a second allele with a CFTR mutation predicted to have residual function.
    • heterozygous for the F508del CFTR mutation and with a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive
  • Subjects with a confirmed diagnosis of CF defined as a sweat chloride value ≥60 mmol/L or chronic sinopulmonary and/or gastrointestinal disease consistent with a diagnosis of CF. Subjects who are homozygous for the F508del-CFTR mutation must have a sweat chloride value ≥60 mmol/L.
  • Subjects with ppFEV1 of ≥40 percentage points at the Screening Visit
  • Subjects with stable CF disease as deemed by the investigator at the Screening Visit.
  • Subjects who are willing to remain on their stable CF medication regimen through Day 14 (Part A) or through Week 24 (Part B) or, if applicable, through the Safety Follow up Visit.
  • Subjects who are able to swallow tablets.
  • Female subjects of must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Day 1 Visit before receiving the first dose of study drug.
  • Subjects of childbearing potential who are sexually active must meet the requirements

Exclusion criteria

Exclusion Criteria:

  • History of any comorbidity reviewed at the Screening Visit that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.
  • Any laboratory abnormalities at the Screening Visit that would interfere with the study assessments or pose an undue risk for the subject.
  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 28 days before Day 1
  • Colonization with organisms associated with a more rapid decline in pulmonary status.
  • A standard 12 lead demonstrating >450 msec at the Screening Visit.
  • History of solid organ or hematological transplantation at the Screening Visit.
  • Ongoing or prior participation in an drug study or use of commercially available CFTR modulator (except physician-prescribed Kalydeco for approved indications) within 30 days of screening.
  • Use of restricted medication or food within a specified duration before the Screening Visit or first dose of study drug and/or unwillingness to maintain the restrictions.
  • History or evidence of cataract, lens opacity, Y-suture, or lamellar rings determined to be clinically significant by the ophthalmologist during the ophthalmologic examination at the Screening Visit.
  • Pregnant and nursing females.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Part A

    Participants weighing \<25 kg received TEZ 50 mg once daily/IVA 75 mg q12h orally for 14 days. Participants weighing ≥25 kg received TEZ 50 mg once daily/IVA 150 mg q12h orally for 14 days.

    Drug: TEZ · Drug: IVA

  • Experimental
    Part B

    Participants weighing \<40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination orally once daily in the morning and IVA 75 mg orally once daily in the evening for 24 weeks. Participants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination orally once daily in the morning and IVA 150 mg orally once daily in the evening for 24 weeks.

    Drug: TEZ/IVA · Drug: IVA

Interventions

  • DrugTEZ

    Also known as: tezacaftor, VX-661

  • DrugTEZ/IVA

    Drug pages: Tezacaftor · Ivacaftor

    Also known as: tezacaftor/ivacaftor, VX-661/VX-770

  • DrugIVA

    Also known as: ivacaftor, VX-770

06

What researchers measure

Primary outcomes

  1. Part A: Maximum Observed Concentration (Cmax) of TEZ and IVA

    Time frame: Day 1 and Day 14

  2. Part A: Area Under the Concentration Versus Time Curve During Dosing Interval (AUCtau) of TEZ and IVA

    Time frame: Day 1 and Day 14

  3. Part B: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Week 28

Secondary outcomes

  1. Part A: Cmax of TEZ Metabolites (M1-TEZ, M2-TEZ) and IVA Metabolites (M1-IVA, M6-IVA)

    Time frame: Day 1 and Day 14

  2. Part A: AUCtau of TEZ Metabolites (M1-TEZ, M2-TEZ) and IVA Metabolites (M1-IVA, M6-IVA)

    Time frame: Day 1 and Day 14

  3. Part A: Number of Participants With AEs and SAEs

    Time frame: Day 1 up to Day 28

  4. Part B: Cmax of TEZ, TEZ Metabolites (M1-TEZ, M2-TEZ), IVA, and IVA Metabolites (M1-IVA, M6-IVA)

    Time frame: Week 16

  5. Part B: AUCtau of TEZ, TEZ Metabolites (M1-TEZ, M2-TEZ), IVA, and IVA Metabolites (M1-IVA, M6-IVA )

    Time frame: Week 16

  6. Part B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline through Week 24

  7. Part B: Relative Change in ppFEV1

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline through Week 24

  8. Part B: Absolute Change in Weight

    Time frame: From Baseline at Week 24

  9. Part B: Absolute Change in Weight-for-age Z-Score

    z-score is a statistical measure to describe whether a mean was above or below the standard. Weight, adjusted for age and sex, was analyzed as weight-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher weight.

    Time frame: From Baseline at Week 24

  10. Part B: Absolute Change in Height

    Time frame: From Baseline at Week 24

  11. Part B: Absolute Change in Height-for-age z-Score

    z-score is a statistical measure to describe whether a mean was above or below the standard. Height, adjusted for age and sex, was analyzed as height-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher height.

    Time frame: From Baseline at Week 24

  12. Part B: Absolute Change in Body Mass Index (BMI)

    BMI was defined as weight in kg divided by height in square meter (m\^2).

    Time frame: From Baseline at Week 24

  13. Part B: Absolute Change in BMI-for-age z-Score

    BMI was defined as weight in kg divided by height in m\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI.

    Time frame: From Baseline at Week 24

  14. Part B: Absolute Change in Sweat Chloride

    Sweat samples were collected using an approved collection device.

    Time frame: From Baseline through Week 4

  15. Part B: Absolute Change in Sweat Chloride

    Sweat samples were collected using an approved collection device.

    Time frame: From Baseline through Week 24

  16. Part B: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: From Baseline through Week 24

07

Results

Posted Dec 5, 2019

Participant flow

Participant flow — Overall Study
MilestonePart APart B
Started1370
Completed1367
Not completed03
Withdrew: Adverse event01
Withdrew: Withdrawal of consent (not due to ae)02

Outcome measures

PrimaryPart A: Maximum Observed Concentration (Cmax) of TEZ and IVA
Time frame:
Day 1 and Day 14
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Part A: Maximum Observed Concentration (Cmax) of TEZ and IVA
nanogram per milliliter (ng/mL)Part A
Day 1: TEZ (<25 Kg)6630 ± 10.3
Day 1: TEZ (≥25 Kg)4310 ± 42.6
Day 14: TEZ (<25 Kg)6300 ± 10.3
Day 14: TEZ (≥25 Kg)5340 ± 49.0
Day 1: IVA (<25 Kg)656
Day 1: IVA (≥25 Kg)1010 ± 64.3
Day 14: IVA (<25 Kg)578 ± 60.4
Day 14: IVA (≥25 Kg)1490 ± 105
PrimaryPart A: Area Under the Concentration Versus Time Curve During Dosing Interval (AUCtau) of TEZ and IVA
Time frame:
Day 1 and Day 14
Reported as:
Geometric mean · hour*nanogram per milliliter (hr*ng/mL)
Part A: Area Under the Concentration Versus Time Curve During Dosing Interval (AUCtau) of TEZ and IVA
hour*nanogram per milliliter (hr*ng/mL)Part A
Day 1: TEZ (<25 Kg)54300 ± 16.2
Day 1: TEZ (≥25 Kg)41600 ± 36.2
Day 14: TEZ (<25 Kg)66500 ± 30.5
Day 14: TEZ (≥25 Kg)71600 ± 61.1
Day 14: IVA (<25 Kg)5050 ± 49.1
Day 14: IVA (≥25 Kg)12400 ± 118
PrimaryPart B: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Week 28
Reported as:
Number · participants
Part B: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsPart B
Participants with AEs65
Participants with SAEs6
SecondaryPart A: Cmax of TEZ Metabolites (M1-TEZ, M2-TEZ) and IVA Metabolites (M1-IVA, M6-IVA)
Time frame:
Day 1 and Day 14
Reported as:
Geometric mean · ng/mL
Part A: Cmax of TEZ Metabolites (M1-TEZ, M2-TEZ) and IVA Metabolites (M1-IVA, M6-IVA)
ng/mLPart A
Day 1: M1-TEZ (<25 kg)1720 ± 3.29
Day 1: M1-TEZ (≥25 kg)1530 ± 22.0
Day 14: M1-TEZ (<25 kg)8360 ± 22
Day 14: M1-TEZ (≥25 kg)5930 ± 19.9
Day 1: M2-TEZ (<25 kg)1130 ± 4.36
Day 1: M2-TEZ (≥25 kg)922 ± 25.8
Day 14: M2-TEZ (<25 kg)6180 ± 27.2
Day 14: M2-TEZ (≥25 kg)5350 ± 27.2
Day 1: M1-IVA (<25 kg)2320
Day 1: M1-IVA (≥25 kg)2430 ± 57.1
Day 14: M1-IVA (<25 kg)1460 ± 34.6
Day 14: M1-IVA (≥25 kg)3420 ± 72.7
Day 1: M6-IVA (<25 kg)849
Day 1: M6-IVA (≥25 kg)1070 ± 55.7
Day 14: M6-IVA (<25 kg)1090 ± 31.4
Day 14: M6-IVA (≥25 kg)2720 ± 59.2
SecondaryPart A: AUCtau of TEZ Metabolites (M1-TEZ, M2-TEZ) and IVA Metabolites (M1-IVA, M6-IVA)
Time frame:
Day 1 and Day 14
Reported as:
Geometric mean · hr*ng/mL
Part A: AUCtau of TEZ Metabolites (M1-TEZ, M2-TEZ) and IVA Metabolites (M1-IVA, M6-IVA)
hr*ng/mLPart A
Day 1: M1-TEZ (<25 kg)36500 ± 5.80
Day 1: M1-TEZ (≥25 kg)27400 ± 26.3
Day 14: M1-TEZ (<25 kg)160000 ± 15.5
Day 14: M1-TEZ (≥25 kg)121000 ± 17.1
Day 1: M2-TEZ (<25 kg)14200 ± 12.3
Day 1: M2-TEZ (≥25 kg)11100 ± 25.9
Day 14: M2-TEZ (<25 kg)137000 ± 32.7
Day 14: M2-TEZ (≥25 kg)119000 ± 27.7
Day 14: M1-IVA (<25 kg)13700 ± 52.1
Day 14: M1-IVA (≥25 kg)30300 ± 81.1
Day 14: M6-IVA (<25 kg)10200 ± 58.5
Day 14: M6-IVA (≥25 kg)26000 ± 70.6
SecondaryPart A: Number of Participants With AEs and SAEs
Time frame:
Day 1 up to Day 28
Reported as:
Number · participants
Part A: Number of Participants With AEs and SAEs
participantsPart A
Participants with AEs12
Participants with SAEs0
SecondaryPart B: Cmax of TEZ, TEZ Metabolites (M1-TEZ, M2-TEZ), IVA, and IVA Metabolites (M1-IVA, M6-IVA)
Time frame:
Week 16
Reported as:
Geometric mean · ng/mL
Part B: Cmax of TEZ, TEZ Metabolites (M1-TEZ, M2-TEZ), IVA, and IVA Metabolites (M1-IVA, M6-IVA)
ng/mLPart B
TEZ (<40 kg)4800 ± 33.7
TEZ (≥40 kg)5870 ± 46.5
M1-TEZ (<40 kg)5310 ± 36.0
M1-TEZ (≥40 kg)5440 ± 61.5
M2-TEZ (<40 kg)4170 ± 47.4
M2-TEZ (≥40 kg)5210 ± 55.0
IVA (<40 kg)725 ± 56.9
IVA (≥40 kg)886 ± 58.7
M1-IVA (<40 kg)1560 ± 54.8
M1-IVA (≥40 kg)1870 ± 50.2
M6-IVA (<40 kg)870 ± 69.2
M6-IVA (≥40 kg)1120 ± 29.5
SecondaryPart B: AUCtau of TEZ, TEZ Metabolites (M1-TEZ, M2-TEZ), IVA, and IVA Metabolites (M1-IVA, M6-IVA )
Time frame:
Week 16
Reported as:
Geometric mean · hr*ng/mL
Part B: AUCtau of TEZ, TEZ Metabolites (M1-TEZ, M2-TEZ), IVA, and IVA Metabolites (M1-IVA, M6-IVA )
hr*ng/mLPart B
TEZ (<40 kg)50300 ± 36.3
TEZ (≥40 kg)60900 ± 50.6
M1-TEZ (<40 kg)104000 ± 44.2
M1-TEZ (≥40 kg)100000 ± 87.2
M2-TEZ (<40 kg)88400 ± 57.0
M2-TEZ (≥40 kg)93600 ± 46.5
IVA (<40 kg)5330 ± 62.2
IVA (≥40 kg)7410 ± 53.8
M1-IVA (<40 kg)12700 ± 55.9
M1-IVA (≥40 kg)17200 ± 40.4
M6-IVA (<40 kg)8140 ± 70.2
M6-IVA (≥40 kg)11100 ± 39.4
SecondaryPart B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline through Week 24
Reported as:
Least squares mean · percentage points
Part B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
percentage pointsPart B
Part B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)0.9 (-0.6 to 2.3)
SecondaryPart B: Relative Change in ppFEV1

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline through Week 24
Reported as:
Least squares mean · percent change
Part B: Relative Change in ppFEV1
percent changePart B
Part B: Relative Change in ppFEV11.4 (-0.4 to 3.1)
SecondaryPart B: Absolute Change in Weight
Time frame:
From Baseline at Week 24
Reported as:
Least squares mean · kg
Part B: Absolute Change in Weight
kgPart B
Part B: Absolute Change in Weight1.7 (1.3 to 2.0)
SecondaryPart B: Absolute Change in Weight-for-age Z-Score

z-score is a statistical measure to describe whether a mean was above or below the standard. Weight, adjusted for age and sex, was analyzed as weight-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher weight.

Time frame:
From Baseline at Week 24
Reported as:
Least squares mean · z-score
Part B: Absolute Change in Weight-for-age Z-Score
z-scorePart B
Part B: Absolute Change in Weight-for-age Z-Score0.00 (-0.05 to 0.05)
SecondaryPart B: Absolute Change in Height
Time frame:
From Baseline at Week 24
Reported as:
Least squares mean · centimeter (cm)
Part B: Absolute Change in Height
centimeter (cm)Part B
Part B: Absolute Change in Height2.7 (2.4 to 2.9)
SecondaryPart B: Absolute Change in Height-for-age z-Score

z-score is a statistical measure to describe whether a mean was above or below the standard. Height, adjusted for age and sex, was analyzed as height-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher height.

Time frame:
From Baseline at Week 24
Reported as:
Least squares mean · z-score
Part B: Absolute Change in Height-for-age z-Score
z-scorePart B
Part B: Absolute Change in Height-for-age z-Score0.00 (-0.05 to 0.05)
SecondaryPart B: Absolute Change in Body Mass Index (BMI)

BMI was defined as weight in kg divided by height in square meter (m\^2).

Time frame:
From Baseline at Week 24
Reported as:
Least squares mean · kg/m^2
Part B: Absolute Change in Body Mass Index (BMI)
kg/m^2Part B
Part B: Absolute Change in Body Mass Index (BMI)0.23 (0.06 to 0.40)
SecondaryPart B: Absolute Change in BMI-for-age z-Score

BMI was defined as weight in kg divided by height in m\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values are indicative of higher BMI.

Time frame:
From Baseline at Week 24
Reported as:
Least squares mean · z-score
Part B: Absolute Change in BMI-for-age z-Score
z-scorePart B
Part B: Absolute Change in BMI-for-age z-Score-0.03 (-0.10 to 0.04)
SecondaryPart B: Absolute Change in Sweat Chloride

Sweat samples were collected using an approved collection device.

Time frame:
From Baseline through Week 4
Reported as:
Least squares mean · millimole per liter (mmol/L)
Part B: Absolute Change in Sweat Chloride
millimole per liter (mmol/L)Part B
Part B: Absolute Change in Sweat Chloride-13.0 (-16.2 to -9.9)
SecondaryPart B: Absolute Change in Sweat Chloride

Sweat samples were collected using an approved collection device.

Time frame:
From Baseline through Week 24
Reported as:
Least squares mean · mmol/L
Part B: Absolute Change in Sweat Chloride
mmol/LPart B
Part B: Absolute Change in Sweat Chloride-14.5 (-17.4 to -11.6)
SecondaryPart B: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
From Baseline through Week 24
Reported as:
Least squares mean · units on a scale
Part B: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
units on a scalePart B
Part B: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score3.4 (1.4 to 5.5)

Adverse events

Collected over Part A: Day 1 up to Day 28; Part B: Day 1 up to Week 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A0/13 (0%)0/13 (0%)12/13 (92.3%)
Part B0/70 (0%)6/70 (8.6%)62/70 (88.6%)
Most frequent serious events
Most frequent serious events
EventPart APart B
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/132/70
ConstipationGastrointestinal disorders0/131/70
Breath odourGastrointestinal disorders0/131/70
SinusitisInfections and infestations0/131/70
Failure to thriveMetabolism and nutrition disorders0/131/70
SnoringRespiratory, thoracic and mediastinal disorders0/131/70
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPart APart B
CoughRespiratory, thoracic and mediastinal disorders3/1325/70
HeadacheNervous system disorders3/136/70
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/1315/70
PyrexiaGeneral disorders1/1313/70
Nasal congestionRespiratory, thoracic and mediastinal disorders2/1310/70
Abdominal painGastrointestinal disorders0/1310/70
VomitingGastrointestinal disorders0/137/70
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/137/70
NasopharyngitisInfections and infestations1/136/70
Upper respiratory tract infectionInfections and infestations0/136/70

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part APart BTotal
<=18 years137083
Between 18 and 65 years000
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Part APart BTotal
Female73441
Male63642
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part APart BTotal
Hispanic or Latino033
Not Hispanic or Latino136780
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part APart BTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American101
White126880
More than one race011
Unknown or Not Reported000
08

Study locations

33 sites
  • Birmingham, Alabama, United States
  • Anchorage, Alaska, United States
  • Little Rock, Arkansas, United States
  • Los Angeles, California, United States
  • Palo Alto, California, United States
  • Aurora, Colorado, United States
  • Wilmington, Delaware, United States
  • Orlando, Florida, United States
  • Saint Petersburg, Florida, United States
  • Atlanta, Georgia, United States
  • Boise, Idaho, United States
  • Indianapolis, Indiana, United States
  • Boston, Massachusetts, United States
  • Minneapolis, Minnesota, United States
  • Kansas City, Missouri, United States
  • Manchester, New Hampshire, United States
  • Buffalo, New York, United States
  • New York, New York, United States
  • Syracuse, New York, United States
  • Winston-Salem, North Carolina, United States
  • Cleveland, Ohio, United States
  • Pittsburgh, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Sioux Falls, South Dakota, United States
  • Austin, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • Norfolk, Virginia, United States
  • Seattle, Washington, United States
  • Milwaukee, Wisconsin, United States
  • Vancouver, British Columbia, Canada
  • Toronto, Ontario, Canada
  • Montréal, Quebec, Canada
09

References and documents

Publications

  • Walker S, Flume P, McNamara J, Solomon M, Chilvers M, Chmiel J, Harris RS, Haseltine E, Stiles D, Li C, Ahluwalia N, Zhou H, Owen CA, Sawicki G; VX15-661-113 Investigator Group. A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis. J Cyst Fibros. 2019 Sep;18(5):708-713. doi: 10.1016/j.jcf.2019.06.009. Epub 2019 Jun 26. PubMed 31253540 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Sep 2018, 22 months.

Results were first posted in Dec 2019, 1 year 3 months after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 22 months is below that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2016
First posted
Nov 2, 2016
StartActual
Nov 2016
Primary completionActual
Sep 2018
CompletionActual
Sep 2018
Results first posted
Dec 5, 2019
Last update
Mar 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02953314
Responsible party
Sponsor
First posted
Nov 2, 2016
Start date
Nov 2016
Primary completion
Sep 2018
Completion
Sep 2018
Results posted
Dec 5, 2019
Last update
Mar 4, 2020

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tezacaftor · Ivacaftor

Start the discussion